Clinical Trials Logo

Oligo-Astrocytoma clinical trials

View clinical trials related to Oligo-Astrocytoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT00795457 Completed - Glioma Clinical Trials

Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas

Start date: January 2009
Phase: Early Phase 1
Study type: Interventional

This is a pilot vaccine study in adults with either WHO grade II astrocytoma, oligoastrocytoma or oligodendroglioma. The purpose of this study is test the safety and efficacy of an experimental tumor vaccine made from peptides and Montanide ISA-51 in combination with the study drug Poly-ICLC. Poly-ICLC, manufactured by Oncovir, Inc., has already been received and generally well tolerated by subjects in earlier studies and has been shown to decrease the size of brain tumors in some cases. The immunological and safety data will be used to decide whether a larger study of clinical efficacy is warranted in each of two patient cohorts.

NCT ID: NCT00114309 Active, not recruiting - Clinical trials for Glioblastoma Multiforme

131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma

Start date: November 2004
Phase: Phase 2
Study type: Interventional

This drug is being developed to treat a type of brain cancer, glioma. This study was developed to evaluate the safety, time to disease progression and survival rates after treatment.